Etanercept biosimilar approval reignites ‘a-flagging’ concerns

The recent TGA approval of the etanercept biosimilar Brenzys™ has reignited concerns around the pharmacist substitution of originator biologics for biosimilars. Marketed by MSD in Australia Brenzys™ is the first biosimilar of Pfizer’s originator drug Enbrel™ and follows hot on the heels of the infliximab biosimilar Inflectra™ which received  a PBS listing in December last ...

Already a member? Login to keep reading

© 2018 the limbic